Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency. Biosimilars are expected to be a cost-effective alternative to high-priced branded biologics, […]readmore
Tags : Yas Holding
Shots: Yas Holding entered into an exclusive license and distribution agreement with Alvogen to commercialize its targeted generic pharmaceuticals portfolio in MENA region The collaboration will expand Alvogen’s presence in […]readmore
Shots: Alvotech to receive ~$45M as up front, equity investment, milestone while Yas Holding has acquired a 2.5% stake in Alvotech business and get rights to commercialize Alvotech’s three biosimilar […]readmore